Join us in Melbourne at our face-to-face NET Patient Education Forum this November. This is a wonderful opportunity to ask “Our Expert NET Clinicians” questions and gain information on current treatments and Clinical Trials.
Date: Thursday 28th November 2024
Time: 5:30pm – 8pm
Venue: Peter MacCallum Cancer Centre
305 Grattan Street, Melbourne Vic 3000
Cost: Free
RSVP: Thursday 21st November. Registration is essential for catering purposes.
There will be plenty of time for questions and discussion at the Forum and you are invited to submit any questions you would like addressed prior to the event. To submit questions or for any further information, please contact info@neuroendocrine.org.au
Time | Speaker | Subject |
5:30pm | Arrival, register and light refreshments | |
6.00pm | Meredith Cummins | Welcome & Acknowledgement of Country |
6:05pm | Professor Michael Michael | Updates on Medical Oncology & Clinical trials |
6:25pm | A/Prof Grace Kong | Updates on Nuclear Medicine & Clinical Trials |
6:45pm | A/Prof Cherie Chiang | Guideline updates for carcinoid crisis in surgery and development of spot urine 5HIAA |
7:05pm | Dr Erin Laing | Nutrition |
7:20pm | Kate Wakelin | NET Nurse Clinics |
7:30pm | Meredith Cummins | NECA update |
7:40pm | Q&A | |
8:00pm | Close |
Prof Michael Michael
Medical Oncologist
Professor Michael is a Consultant Gastrointestinal and Neuroendocrine Medical Oncologist, co-chair of the Peter Mac ENETs Centre of Excellence and Medical/Trial lead for the Upper GI Tumour Stream. He graduated from Monash University, completed his medical oncology training at the Peter Mac followed by a 2 year Fellowship at the Princess Margaret Hospital, Ontario Canada.
Returning to Peter Mac as a Consultant Oncologist in 1998, he has now over 25 years of considerable clinical experience in gastrointestinal and neuroendocrine oncology. This is in parallel with the development of clinical and translational research programs and trials in the areas of oncological pharmacology, dose individualisation, pharmacogenomics, novel multi-modality combination therapies both in gastrointestinal and neuroendocrine oncology. Current projects include the identification of novel genetic biomarkers to predict the clinical behaviour of patients with NETs, the establishment of DPYD/UGT1A1 screening programs at Peter Mac and in regional/rural centres, assessing novel chemoradiation therapies (including with immunotherapy) in patients with gastric and rectal cancers, combination treatments to increase the effects of PRRT, and associated translational studies with several laboratory groups based at Peter Mac with the supervision of PhD students.
A/Prof Grace Kong Nuclear Medicine Physician Grace Kong is a Nuclear Medicine Physician at the Peter MacCallum Cancer Centre (PMCC) in Melbourne Australia, a Clinical Associate Professor at the University of Melbourne, Sir Peter MacCallum Department of Oncology. She is the Co-Chair of the Neuroendocrine Tumour (NET) Unit, a European Neuroendocrine Tumor Society (ENETS) Center of Excellence. She has clinical leadership roles as the Lead of Radionuclide Therapy at PMCC, Chair of the NET multidisciplinary meeting (MDM), and the Nuclear Medicine Lead for the upper gastrointestinal tumour MDM. She was a recipient of the Foundation Discovery Partner Fellowship grant award. Grace graduated from Monash University (Australia) and previously completed a fellowship in PET and radionuclide therapy at the Royal Marsden Hospital in UK. She has broad clinical and research interests in using molecular imaging to characterize cancer, with a focus on advancing theranostics, radionuclide therapy and precision medicine for treating NET, endocrine, prostate and other cancers. She has published multiple practice-changing peer-reviewed articles, particularly in NET and peptide receptor radionuclide therapy (PRRT). She is the CPI / PI for 10+ active prospective national and international collaborative diagnostic and theranostics trials and is a co-investigator of many oncologic studies, particularly in NET, prostate cancer and thyroid cancer. She actively participates in research and education at national and international meetings, is a member of the AANMS committee for Theranostics education. She is engaged in patient education and advocacy as a committee member of Neuroendocrine Cancer Australia. Her vision is to be a lead clinician-researcher, to improve patient outcomes through collaborative prospective clinical and translational research. |
A/Prof Cherie Chiang
Endocrinologist & Pathologist (Chemical)
A/Prof Chiang is a dual qualified endocrinologist and chemical pathologist. She is the Head of Chemical Pathology at Melbourne Health, the Head of Bone at Austin Health, Endocrine partner at ENETS Peter MacCallum Cancer Centre, ANZBMS Councillor and RACP Council Member (Endocrinology and Chemical Pathology representative).
Dr Erin Laing NET Specialist Dietitian Dr Erin Laing is Senior Clinical Dietitian and researcher in the Nutrition and Speech Pathology Department at Peter MacCallum Cancer Centre, with over 12 years experience in oncology nutrition and managing all cancer types. She has a particular interest and experience in the nutritional management of gastrointestinal cancers and neuroendocrine tumours and has led the nutrition service for both upper and lower gastrointestinal cancers over her time at Peter Mac. Erin is passionate about optimising models of care to improve the nutritional management and quality of life for cancer patients. She led the implementation of a dedicated nutrition service for neuroendocrine tumours and it’s integration into the multidisciplinary neuroendocrine clinic in 2016-2017.
|
Kate Wakelin
NET Clinical Nurse Consultant
Kate is a Registered Nurse with a Graduate Diploma in Psycho-Oncology, also holding a Certificate IV in Workplace Assessment and Training, as well as post graduate qualifications in breast, prostate, and lung cancer nursing.
Kate has a career spanning more than 30 years in cancer care, in a mixture of clinical, program management, and supportive care roles. The focus for much of this work has been in providing specialist cancer information and support, in the provision of helplines, face-to-face and online peer support and education programs, and health professional networks. Kate has specific experience and expertise in the nursing care of people with neuroendocrine tumours, with this being her primary area of focus for the last decade.
Throughout her career, Kate has maintained a passion for creating and maintaining innovative programs that strengthen the delivery of holistic and supportive care.
Meredith Cummins CEO – NeuroEndocrine Cancer Australia Meredith has been working at NeuroEndocrine Cancer Australia since February 2018 and has held the position of Project Officer / CRA & Telehealth Nurse prior to commencing the role of CEO in October 2022. Since commencing with NeuroEndocrine Cancer Australia Meredith has been fundamental in the development of PLANET Registry and Patient App, the NET Optimal Care Pathway, our fully accredited GP and Nurse Education Modules and the Living with NETs Program. She is actively involved in the Support Groups nationally and has coordinated and facilitated many Patient Education Forums across Australia. Meredith is a highly driven and dedicated health professional who thrives on delivering world class care and support to cancer patients and enhancing the skills of other health professionals to deliver this care. She has been involved in Oncology for over 30 years in metropolitan, rural, international, public and private settings. She has been a key player instrumental in the commissioning and establishment of four private cancer care facilities in New South Wales. Meredith has a wealth of experience in comprehensive cancer care, accreditation and licensing processes, governance (Board of Directors and Medical Advisory Committees), quality management systems, fundraising, liaison with pharmaceutical companies and Philanthropic groups and all aspects of practice management. She enjoys creating and developing dynamic teams so that cancer patients can benefit from Best Practice care and health professionals can develop skills and enhance their career pathways. Meredith has a passion for developing and delivering world class cancer care and support to neuroendocrine patients across Australia. |